| 证券代码：603579 | 证券简称：荣泰健康 公告编号：2023-050 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | 上海荣泰健康科技股份有限公司 关于参与认购私募股权投资基金份额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （1）由于股权投资合伙企业具有投资周期长、流动性低的特点，公司本次 投资可能面临较长的投资回收期； （2）受宏观经济的影响、投资标的的选择、行业环境以及基金自身管理和 技术等多种因素影响，存在不能实现预期效益的风险； （3）合伙企业设立运营后，存在因国家政策、法律法规、宏观经济影响、 行业宏观环境、投资标的选择以及投资管理不确定性，无法达成预期收益或亏损 的风险，但公司作为合伙企业的有限合伙人，承担的投资风险敞口不超过公司出 资额，即 2,000 万元人民币，敬请广大投资者注意投资风险。 一、对外投资概述 （一）对外投资的基本情况 上海荣泰健康科技股份有限公司（以下简称"公司"）在确保满足日常经营 资金需求、总体投资风险可控的前提 ...

| 证券代码：603579 | 证券简称：荣泰健康 公告编号：2023-047 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | 上海荣泰健康科技股份有限公司 关于使用可转债闲置募集资金进行现金管理的进展 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：可转让大额存单 投资金额：人民币 8,800 万元 现金管理期限：持有该存单期限不超过 12 个月 已履行的审议程序：上海荣泰健康科技股份有限公司（以下简称"公司"） 于 2023 年 4 月 6 日召开第四届董事会第五次会议、第四届监事会第四次会 议，于 2023 年 5 月 5 日召开 2022 年年度股东大会，分别审议通过了《关于 公司 2023 年度使用可转债闲置募集资金进行现金管理的议案》，同意公司 及子公司使用最高不超过人民币 3 亿元的公开发行可转换公司债券（以下简 称"可转债"）闲置募集资金适时投资安全性高、流动性好、有保本约定的理 财产品或结构性存款，授权期限为自公司 2022 年年度股东大 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately RMB 889.90 million, a decrease of 19.20% compared to RMB 1,101.36 million in the same period last year[19]. - Net profit attributable to shareholders for the first half of 2023 was approximately RMB 104.92 million, an increase of 21.48% from RMB 86.37 million in the previous year[19]. - The net profit after deducting non-recurring gains and losses was approximately RMB 95.61 million, up 19.63% from RMB 79.92 million in the same period last year[19]. - Basic earnings per share for the first half of 2023 were RMB 0.78, representing a 20.00% increase from RMB 0.65 in the same period last year[19]. - Diluted earnings per share for the first half of 2023 were RMB 0.77, an increase of 20.31% from RMB 0.64 in the previous year[19]. - The company reported a total comprehensive income of 54,380.62 million RMB for the first half of 2023, reflecting a significant increase compared to the previous period[179]. - The net profit attributable to shareholders for the first half of 2023 was 95,658.44 million, showing a growth of 6.10% compared to the previous year[172]. Cash Flow and Assets - The net cash flow from operating activities increased by 66.67% to approximately RMB 164.08 million, compared to RMB 98.45 million in the previous year[19]. - The company's cash and cash equivalents at the end of the period were 1.22 billion RMB, accounting for 36.89% of total assets, a decrease of 8.10% from the previous year[54]. - The company's cash and cash equivalents as of June 30, 2023, are 1,222,105,262.83 yuan, down from 1,329,776,484.49 yuan at the end of 2022[137]. - The total current assets decreased from 2,270,578,335.21 yuan to 2,023,612,212.08 yuan[137]. - The total assets of the company at the end of the first half of 2023 were reported at 3,941,290.0 million, compared to 3,776,170.3 million at the end of the previous year, marking a growth of approximately 4.36%[169]. - The total assets of the company reached 3,896,930 million, demonstrating growth in asset base[161]. Investment and Expansion - The company has established over 1,000 offline stores in China and maintains a presence on major e-commerce platforms such as Tmall, JD.com, and Douyin[40]. - The company aims to provide a healthy and fashionable lifestyle for global users, aligning with its vision of serving millions of families[28]. - The company plans to adjust its product strategy and implement proactive sales policies to boost overseas orders in response to varying market conditions[46]. - The company is actively developing new products in collaboration with ODM partners and expanding its market presence beyond Korea to other regions[81]. - The company plans to expand its market presence and invest in new product development to drive future growth[147]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[171]. Research and Development - The company completed 9 R&D projects and obtained 6 new invention patents, 51 utility model patents, and 11 design patents during the reporting period[48]. - The company aims to enhance its research and development efforts to innovate and improve product offerings[162]. - The company has initiated research and development for new technologies aimed at enhancing operational efficiency and customer engagement[171]. Market Trends and Strategies - The global massage equipment market is projected to reach approximately $23.6 billion by 2026, driven by increasing health awareness and disposable income in China[27]. - The domestic market shows a strong trend in consumer spending on massage and health care products, with significant growth in both domestic and international orders[41]. - The company employs an order-based production model, ensuring efficient management of manufacturing processes[38]. - The company utilizes a dual sales model for domestic and international markets, with a focus on ODM for global brands[34]. - The massage equipment industry is characterized by rapid technological advancements, integrating various high-tech fields[27]. Financial Management and Risks - The company faces risks from raw material price fluctuations, as over 80% of its cost structure is attributed to raw materials, which could impact net profit growth if prices rise significantly[79]. - The company has a significant reliance on BODYFRIEND, with its sales contributing a substantial portion of revenue; any adverse changes in this relationship could negatively affect performance[80]. - The company is managing foreign exchange risks through various strategies, including settling contracts in RMB and using hedging tools[83]. - The company emphasizes a diversified procurement strategy to mitigate risks associated with raw material shortages[39]. Shareholder and Stock Information - The total number of shareholders reached 12,065 by the end of the reporting period[115]. - The company has 138,973,433 unrestricted circulating shares, accounting for 99.29% of total shares[109]. - The top ten shareholders hold a total of 100,000,000 shares, with Lin Qi holding 34,900,230 shares (25.11%) and Lin Guangrong holding 21,499,870 shares (15.47%) [117]. - The company has approved a foreign exchange derivative trading limit of up to USD 300 million, with a current position accounting for 13.20% of this limit[68]. - The company announced the repurchase and cancellation of 1,000,000 restricted stock units due to unmet performance conditions in the 2021 incentive plan[90]. Legal and Compliance - The company is currently involved in a lawsuit with a claim for economic damages of 99 million yuan related to patent infringement on massage chairs, with the case still pending judgment[105]. - The company’s revenue recognition and accounting policies are in accordance with the relevant enterprise accounting standards, ensuring accurate financial reporting[190].

关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 08 月 08 日（星期二）至 08 月 14 日（星期一）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 Public@rotai.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 上海荣泰健康科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 8 日 发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年 半年度经营成果、财务状况，公司计划于 2023 年 08 月 15 日上午 10:00-11:00 举 行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 | 证券代码：603579 | 证券简称：荣泰健康 公告编号：2023-046 | | --- | --- | | 转债代码：113606 | ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥385,718,637.33, representing a decrease of 31.71% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥37,501,251.13, down 35.70% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,866,712.47, a decline of 39.52% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.28, reflecting a decrease of 36.36% year-over-year[6] - The diluted earnings per share for Q1 2023 was also ¥0.28, down 33.33% from the same period last year[6] - Total operating revenue for Q1 2023 was CNY 385.72 million, a decrease of 31.7% compared to CNY 564.80 million in Q1 2022[19] - Net profit for Q1 2023 was CNY 37.68 million, a decline of 35.6% from CNY 58.56 million in Q1 2022[20] - Basic earnings per share for Q1 2023 were CNY 0.28, compared to CNY 0.44 in Q1 2022[21] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,259,730,630.27, down 4.79% from the end of the previous year[6] - Total assets as of Q1 2023 were CNY 3.26 billion, a decrease from CNY 3.42 billion at the end of Q1 2022[16] - Total liabilities as of Q1 2023 were CNY 1.35 billion, down from CNY 1.55 billion in Q1 2022[16] - Shareholders' equity attributable to the parent company was ¥1,903,618,815.29, an increase of 2.01% compared to the end of the previous year[6] - Shareholders' equity as of Q1 2023 was CNY 1.91 billion, an increase from CNY 1.87 billion in Q1 2022[17] Cash Flow - The company reported a net cash flow from operating activities of ¥21,078,065.76 for Q1 2023, with no applicable year-over-year comparison[5] - The net cash flow from operating activities for Q1 2023 was 21,078,065.76, a significant improvement from -27,415,890.24 in Q1 2022, indicating a recovery in operational efficiency[24] - Total cash inflow from operating activities was 448,101,157.18, while cash outflow was 427,023,091.42, resulting in a net cash inflow of 21,078,065.76 for the quarter[24] - Cash received from sales of goods and services in Q1 2023 was CNY 392.97 million, down 33.2% from CNY 589.07 million in Q1 2022[23] - The total cash and cash equivalents at the end of Q1 2023 were 1,242,747,863.10, down from 1,284,376,555.91 at the end of Q1 2022[25] Investments and Expenses - Research and development expenses for Q1 2023 were CNY 17.23 million, a decrease of 31.5% from CNY 25.17 million in Q1 2022[19] - Financial expenses for Q1 2023 were CNY 5.39 million, compared to CNY 4.86 million in Q1 2022[20] - Cash inflow from investment activities was 237,989,336.56, compared to 612,494,044.13 in the previous year, reflecting a decrease in investment returns[25] - The cash outflow for investment activities was 194,998,606.79, down from 542,435,408.90 in Q1 2022, suggesting a reduction in capital expenditures[25] Legal Matters - The company is currently involved in a legal dispute with a claim for economic damages of RMB 99 million related to patent infringement, which is still pending court judgment[13] - The company has taken proactive measures to respond to the ongoing litigation and is contesting the claims made against it[13] - The company has not provided specific guidance for future performance in this report, but it is actively monitoring market conditions and legal developments[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,229[10] - The company reported a total of 3,348,479 shares held in its repurchase account, accounting for 2.39% of the total shares as of March 31, 2023[12] Other Financial Metrics - The weighted average return on equity for Q1 2023 was 1.99%, a decrease of 1.24 percentage points compared to the end of the previous year[6] - As of March 31, 2023, the company's cash and cash equivalents amounted to RMB 1,242,747,863.10, a decrease from RMB 1,329,776,484.49 as of December 31, 2022, representing a decline of approximately 6.5%[14] - The total current assets as of March 31, 2023, were RMB 2,038,128,218.89, down from RMB 2,270,578,335.21 at the end of 2022, indicating a decrease of about 10.2%[15] - The company's accounts receivable increased to RMB 106,227,100.14 from RMB 95,069,521.56, reflecting a growth of approximately 11.4%[15] - The inventory level decreased to RMB 177,040,326.87 from RMB 205,227,948.56, showing a reduction of around 13.7%[15] - Long-term equity investments were reported at RMB 58,586,718.35, slightly down from RMB 59,082,899.43, indicating a decrease of about 0.8%[15] - The total non-current assets as of March 31, 2023, were RMB 1,221,602,411.38, an increase from RMB 1,153,246,826.81 at the end of 2022, representing a growth of approximately 5.9%[15]

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2023-027 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于召开 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 05 月 08 日（星期一）至 05 月 12 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 Public@rotai.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 三、参加人员 总经理、董事：林琪先生 上海荣泰健康科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2023 年第一季度报告，为便于广大投资者更全面深入地了解公司 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 05 月 15 日上午 09:00- 10:00 举行 2023 年第一季度业绩说明会， ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2023-024 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 04 月 18 日（星期二）下午 13:00-14:00 会议召开方式：上证路演中心网络文字互动 投资者可于 2023 年 04 月 11 日（星期二）至 04 月 17 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 Public@rotai.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海荣泰健康科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 7 日 发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 2023 年 04 月 18 ...

2022年年度报告 公司代码：603579 公司简称：荣泰健康 转债代码：113606 转债简称：荣泰转债 荣泰，更专业的按摩椅 上海荣泰健康科技股份有限公司 2022 年年度报告 ...

2022 年第三季度报告 证券代码：603579 证券简称：荣泰健康 上海荣泰健康科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | 项目 | 本报告期 | 本报告期 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 比上年同 | | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 460,877,983.10 | -25.26 | 1,562,236,538.61 | -16.24 | | 归属于上市公司股东的 | 39,299,476.20 | -18.52 | 125,666,979.14 | -33.37 | | 净利润 | | | | | | 归属于上市公司股东的 ...

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 1,101,358,555.51, a decrease of 11.78% compared to RMB 1,248,377,561.46 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was RMB 86,367,502.94, down 38.47% from RMB 140,366,552.96 in the previous year[21]. - The net cash flow from operating activities decreased by 47.64%, amounting to RMB 98,446,913.62 compared to RMB 188,022,479.97 in the same period last year[21]. - Basic earnings per share for the first half of 2022 were RMB 0.65, a decline of 36.89% from RMB 1.03 in the same period last year[22]. - The weighted average return on equity decreased to 4.78%, down 3.48 percentage points from 8.26% in the previous year[22]. - The company reported a decrease of 28.37% in net profit after deducting non-recurring gains and losses, totaling RMB 79,921,203.93 compared to RMB 111,575,789.90 in the previous year[21]. - The company reported a significant increase in management expenses by 35.69% due to increased share-based payments compared to the previous year[65]. - The total comprehensive income for the first half of 2022 was CNY 85,488,588.12, a decrease of 38.4% from CNY 138,829,336.35 in the first half of 2021[144]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 3,300,276,316.39, an increase of 0.68% from RMB 3,277,932,920.71 at the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were RMB 1,774,162,416.72, a slight decrease of 0.12% from RMB 1,776,370,370.24 at the end of the previous year[21]. - Cash and cash equivalents at the end of the period reached ¥1,161,888,674.51, representing 35.21% of total assets, an increase of 4.75% year-over-year[68]. - Accounts receivable amounted to ¥147,652,941.81, accounting for 4.47% of total assets, with a year-over-year increase of 3.50%[68]. - Inventory decreased to ¥265,563,039.84, representing 8.05% of total assets, reflecting a decline of 5.01% compared to the previous year[68]. - Fixed assets totaled ¥495,386,136.35, making up 15.01% of total assets, down by 2.63% year-over-year[69]. - Short-term borrowings increased significantly to ¥228,805,644.52, which is 6.93% of total assets, marking a 99.36% increase from the previous year[69]. - The total liabilities as of June 30, 2022, were CNY 1,544,986,253.01, slightly down from CNY 1,551,197,088.41 at the beginning of the year[140]. Market and Industry Insights - The global market for massage equipment exceeded $15 billion in 2019, with China becoming the fastest-growing region for demand[28]. - The market size of China's massage appliance industry was 8.75 billion yuan in 2021, projected to reach 15.27 billion yuan by 2026[28]. - The massage equipment industry is expected to grow significantly due to increasing health awareness and the aging population in China[28]. - The company focuses on the design, R&D, production, and sales of massage equipment, aiming to provide a healthy lifestyle for global users[32]. - The company operates under a multi-channel sales model, including direct sales, e-commerce, and ODM for international markets[36]. - The company’s main products include full-function massage chairs and portable massage devices, catering to various user needs[32]. - The company emphasizes the integration of traditional Chinese medicine with modern technology in its product development[26]. Strategic Initiatives - The company aims to optimize internal management and strengthen product segmentation to adapt to market challenges and maintain its industry position[47]. - The company plans to focus on market expansion and new product development in the upcoming quarters[139]. - The company has initiated a strategic acquisition plan, targeting companies that align with its growth objectives, with a budget of 200,000 million for potential acquisitions[162]. - The company has actively expanded its online presence, particularly in the low-price segment, and has engaged in live-streaming sales to enhance brand visibility[53]. - The company launched new high-end products, including the M810 and M880 series, aimed at enhancing brand image and increasing market share in the premium segment[56]. Risks and Challenges - The company has outlined potential risks in its management discussion and analysis section, advising investors to be cautious[9]. - The company faces risks related to fluctuations in raw material prices, which could directly impact product costs and profitability[85]. - Increased competition in the massage equipment market has led to a focus on brand reputation and product functionality, with the company planning to enhance R&D investment to maintain technological leadership[89]. - The company primarily settles its export business in USD, exposing it to foreign exchange risks, which it aims to mitigate through various strategies including RMB settlement and hedging tools[88]. Corporate Governance and Compliance - The company has no significant litigation or arbitration matters during the reporting period[103]. - The company has fulfilled all commitments related to its initial public offering and refinancing[100]. - The company has maintained good integrity status, with no overdue debts or unfulfilled court judgments[103]. - The company has established a dedicated account for the management of the raised funds, in compliance with regulatory requirements[124]. - The company has confirmed that there are no significant doubts regarding its ability to continue as a going concern for the next 12 months[181].